Top News
High Level of Accuracy of ctDNA-Based Assays for Assignment of Molecularly Targeted Therapy in Advanced Breast Cancer
Greater Subcutaneous Fat Improves mCRPC Treatment Response
Neoadjuvant Chemo May Improve Overall Survival in UTUC
Cannabinoid Receptor CB2 Is a Potential Prognostic Biomarker in NSCLC
Common Cardiovascular Drugs Associated With Reduced Lung Cancer Mortality
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
Acute Medical Oncology Admissions During the COVID-19 Pandemic
Venetoclax With 10-day Decitabine May Induce High Activity in High-Risk Acute Myeloid Leukemia
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Earlier Surrogate for Survival After RP Relapse Possibly Identified
PARP Inhibitor Prolongs Overall Survival in mCRPC
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Dabrafenib and Trametinib Show Promise in Advanced Cholangiocarcinoma
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation. -
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials. -
ESMO 2020 Coverage
Our complete coverage of the European Society for Medical Oncology 2020 virtual meeting. -
With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era. -
Triple Therapy for CLL Shows Promise in Phase 2 Trial
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax. -
Study Documents Real-World Survival Improvement for Non-Small Cell Lung Cancer
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013. -
American Cancer Society Updates Cervical Cancer Screening Guidelines
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
More Features
Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Communicating With Patients in Oncology About Care During the COVID-19 Pandemic
How to explain adjustments to cancer care due to the COVID-19 pandemic and ease patients’ fears about the impact of those changes.
Can Earlier Mammographic Screenings Affect Mortality Rates?
When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
Prostate Cancer Metastasizes by Hijacking a Developmental Epigenetic Program
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
-
Loading...
-
Loading...
